This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment (KOSMOS)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: October 14, 2008
Last updated: February 21, 2011
Last verified: February 2011
The purpose of this study is to ensure the quality of the COPD treatment in primary care by implementing planned follow-up visits, where the disease condition is evaluated and optimised in accordance with the national COPD recommendations. If relevant the general practitioner (GP) will refer patients to COPD rehabilitation conducted by relevant municipality rehabilitation teams. Secondarily the purpose is to improve collaboration and communication between the local hospital pulmonologist, GPs and the municipality rehabilitation team

COPD Chronic Diseases

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Control visits at General practitioners [ Time Frame: 6-12 months ]
  • Lung function measured by spirometry [ Time Frame: 6-12 months ]

Secondary Outcome Measures:
  • Dyspnoea on MRC scale [ Time Frame: 6-12 months ]
  • Smoking status [ Time Frame: 6-12 months ]
  • Rehabilitation completed in the municipality rehabilitation team [ Time Frame: 6-12 months ]

Enrollment: 936
Study Start Date: October 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   35 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diagnosed patients with COPD, verified by spirometry in general practise and/or municipalities.

Inclusion Criteria:

  • COPD diagnose, verified by spirometry
  • Having given informed consent

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00772733

Research Site
Bjerringbro, Viborg, Denmark
Research Site
Moldrup, Viborg, Denmark
Research Site
Skals, Viborg, Denmark
Research Site
Aalborg, Denmark
Research Site
Arhus, Denmark
Research Site
Klarup, Denmark
Research Site
Orum, Denmark
Research Site
Skive, Denmark
Research Site
Spottrup, Denmark
Research Site
Stoholm, Denmark
Research Site
Viborg, Denmark
Sponsors and Collaborators
Study Chair: Michael Skov Jensen, MD Region Hospital Viborg, DK
Study Chair: Tina Brandt Sorensen, MD Region Hospital Horsens, DK
Principal Investigator: Ove Grann Aalborg
  More Information

Responsible Party: Björn.E.Eriksson, MD, VP Medical, AstraZeneca Pharmaceuticals Identifier: NCT00772733     History of Changes
Other Study ID Numbers: NIS-RDK-DUM-2007/1
Study First Received: October 14, 2008
Last Updated: February 21, 2011

Keywords provided by AstraZeneca:
Quality assurance
chronic care model

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes processed this record on August 21, 2017